MOCON Expands Board; Names Two New Directors to its Board

  MOCON Expands Board; Names Two New Directors to its Board

Business Wire

MINNEAPOLIS -- December 03, 2012

MOCON, Inc. (NASDAQ: MOCO) today announced that it has expanded its Board of
Directors from six to eight directors and that Bradley D. Goskowicz and David
J. Ward have joined its Board to fill the two new seats. Mr. Goskowicz will
also initially serve on the compensation committee of the Board, while Mr.
Ward will initially serve on the audit committee.

Mr. Goskowicz is currently the Chief Executive Officer of Microbiologics,
Inc., a private medical device company that is the leading provider of
biomaterials used for quality control in microbiology laboratories in the
food, water, pharmaceutical and other markets. Prior to joining
Microbiologics, Inc., Mr. Goskowicz was the Vice President of Marketing and
Clinical Site Development at Myocor, Inc., a venture backed, development stage
medical device company, and has held senior sales, marketing, and leadership
positions with companies such as Johnson & Johnson, Medtronic, Inc. and
Thoratec Corporation.

Mr. Ward is currently a General Manager of Cargill Process Optimizers, a
provider of technical services and software that assists many of the largest
food and beverage companies improve efficiencies worldwide. Prior to joining
Cargill, Mr. Ward was the President, CEO and Director of Braas Company, a
distributor of factory automation solutions for discrete manufacturers, and
has held senior general management positions with companies such as Emerson
Electric and Rosemount Inc.

“We are excited to have these two experienced executives join our Board of
Directors. Each brings a set of skills in a major growth market where our
company excels, namely the food packaging and processing industry, and the
health care and medical device market. We look forward to the contribution
these gentlemen will make to MOCON’s growth and success,” said Robert L.
Demorest, MOCON President and CEO.

About MOCON

MOCON is a leading provider of detectors, instruments, systems and consulting
services to research laboratories, production facilities, and quality control
and safety departments in the medical, pharmaceutical, food and beverage,
packaging, environmental, oil and gas and other industries worldwide. See
www.mocon.com for more information.

This press release contains forward-looking statements that are made pursuant
to the safe harbor provisions of the Private Securities Litigation Reform Act
of 1995. These forward-looking statements include statements that can be
identified by words such as “will,” “may,” “expect” or other similar
expressions. All forward-looking statements speak only as of the date of this
press release. MOCON undertakes no obligation to update or revise any
forward-looking statement. There are important factors that could cause actual
results to differ materially from those anticipated by the forward-looking
statements made in this press release. These factors include, but are not
limited to, the integration and performance of Dansensor, competition and
technological change, worldwide economic and political stability, setbacks in
product development programs, order cancellations, dependence on certain key
industries, and other factors set forth in the company’s Annual Report on Form
10-K for the year ended December31, 2011 and other documents MOCON files with
or furnishes to the Securities and Exchange Commission.

MOCON's shares are traded on the NASDAQ Global Market System under the symbol
                                    MOCO.
MOCON is a registered trademark of MOCON, Inc.; other trademarks are those of
                          their respective holders.

Contact:

MOCON, Inc.
Darrell Lee, CFO/VP, 763-493-6370
www.mocon.com